STOCKS TELEGRAPH

Tag: NASD:SBFM

  • Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma, Inc. (NASDAQ: SBFM) stock saw a sharp increase after the release of its 2024 financial report. SBFM shares rose 55.50% to $3.25 as of the most recent pre-market check. On Tuesday, April 1, 2025, the company formally submitted its annual report on Form 10-K, demonstrating remarkable financial expansion.

    Initiatives for Sales Growth and Expansion

    In 2024, Sunshine Biopharma reported a significant growth in sales, reaching $34.9 million, a noteworthy 45% increase over $24.1 million in the prior year. In order to finance the growth of its sales activities, SBFM also successfully concluded an underwritten public offering, raising about $10 million in gross revenues.

    Sunshine Biopharma introduced 13 new generic prescription medications in the last year, greatly expanding its pharmaceutical offering. Nine of these were disseminated through strategic partnerships, while four were introduced under cross-licensing agreements. Additionally, Health Canada granted SBFM regulatory authority to sell NIOPEG, a NEULASTA biosimilar, enhancing its portfolio of cancer medications.

    Breakthrough Therapeutics Research

    With its discoveries published in the Journal of Medicinal Chemistry, Sunshine Biopharma also achieved significant strides in therapeutic development. In a mouse model of SARS-CoV-2 infection, the study demonstrated the sub-micromolar potency and great in vivo efficiency of Sunshine Biopharma’s new coronavirus PLpro inhibitor,

    That highlighted its exceptional efficacy and was an important milestone in the company’s continuous attempts to create novel treatments for serious illnesses is this peer-reviewed study.

    Furthermore, Sunshine Biopharma’s K1.1 mRNA Lipid Nanoparticle showed potential as a new therapeutic agent for human hepatocellular carcinoma after completing proof-of-concept animal model studies. As the third most common cause of cancer-related fatalities globally, this kind of liver cancer continues to be a serious global health problem.

    Prospects for the Future and Strategic Development

    Sunshine Biopharma is unwavering in its desire to turn a profit and further its in-house medication research initiatives. As it works to introduce new life-saving medications to the market, SBFM expects to see further growth prospects in 2025 and beyond.

  • Sunshine Biopharma (SBFM) Shares Surge Following Key Drug Launch

    Sunshine Biopharma (SBFM) Shares Surge Following Key Drug Launch

    Shares of Sunshine Biopharma, Inc. (NASDAQ: SBFM) are on a significant boost following the announcement of a new drug launch. As of the latest check, SBFM stock was priced at $3.37, reflecting its robust 13.47% increase on the US stock charts. This surge underscores investor optimism surrounding the company’s expanding portfolio and recent innovations.

    Launch of Generic Bilastine in Canada

    Nora Pharma Inc., a fully owned Canadian subsidiary of Sunshine Biopharma, has introduced the new generic prescription drug bilastine to the Canadian market. Bilastine and other second-generation antihistamines are widely known for their capacity to treat allergic rhinitis and urticaria. The generic form of Blexten, manufactured by Nora Pharma, relieves allergy symptoms in 20 mg capsules.

    As part of a thriving global industry, the Canadian market for bilastine was valued at $1.3 billion in 2023 and is projected to increase at a compound annual growth rate of 6.6% to reach $2.3 billion over the next six years. A variety of reasons, such as increased healthcare spending and knowledge of allergic problems, are supporting the market for antihistamines like Bilastine.

    Expansion in Generic Drug Market

    Bilastine marks the fourth product launched by Sunshine Biopharma in 2024, signifying the company’s growing presence in the Canadian generic drugs market. By means of well-timed product launches, SBFM is gradually increasing its market share in this profitable industry.

    Developments in the Treatment of Liver Cancer

    Sunshine Biopharma also reported encouraging outcomes from preclinical mouse model trials of their K1.1 mRNA product, which is intended to treat human hepatocellular carcinoma (HCC). Despite the availability of first- and second-line treatments, the five-year survival rate for HCC, the most common primary liver cancer, is just 18–21%.

    The company’s K1.1 mRNA technology proved capable of dose-dependently penetrating cancerous liver cells and successfully stopping their proliferation. Additional studies are underway to refine dosing and establish the therapeutic window for future applications in HCC treatment.

    With a strong drug pipeline and continued innovation, Sunshine Biopharma (SBFM) is poised to expand its market influence while addressing critical healthcare challenges. Investors remain optimistic about the company’s trajectory amid these dynamic developments.